Apoptogen and Exogen Neurosciences Merge Talents

Ottawa-based Apoptogen Inc. and Exogen Neurosciences of Montreal, two privately held biotechnology companies, announced on June 1, 2000 that they have merged to become “Aegera Therapeutics Inc.” The merger, by way of amalgamation, is a strategic move designed to accelerate the time to market for each company’s drug products by bringing together their complementary skill bases.

The merged company will focus on neuroscience and cancer research. Apoptogen has uncovered important clues about the genes that control apoptosis, which the body uses to eliminate old, unhealthy or damaged cells, as well as a fundamental biological mechanism that has applications for a broad range of diseases. Exogen Neurosciences’ closely related research concentrates on stopping the signals from genes which turn cells on or off, triggering diseases and disorders.

Borden Ladner Gervais LLP acted for Apoptogen, with a team comprised of Timothy McCunn, Patricia John and Bernard Roach. Sharon Druker and Michelle Dayagi of Sproule, Castonguay, Pollack represented Exogen Neurosciences. The deal was strongly supported by the companies’ respective venture capital and institutional investors, who were represented by Paul Marcotte of Desjardins Ducharme Stein Monast.


Patricia A. John Timothy J. McCunn Paul Marcotte Bernard G. Roach Sharon G. Druker